VIPoma secondary prevention

Revision as of 00:40, 30 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma secondary prevention

CDC on VIPoma secondary prevention

VIPoma secondary prevention in the news

Blogs on VIPoma secondary prevention

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

Effective measures for the secondary prevention of VIPoma include history and physical examination, serum VIP levels and indicated markers, and multi-phasic CT scan or MRI.

Secondary Prevention

Effective measures for the secondary prevention of VIPoma include:[1][2][3]

Note: These follow-up should be done every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter.

References

  1. Kulke, Matthew H.; Benson, Al B.; Bergsland, Emily; Berlin, Jordan D.; Blaszkowsky, Lawrence S.; Choti, Michael A.; Clark, Orlo H.; Doherty, Gerard M.; Eason, James; Emerson, Lyska; Engstrom, Paul F.; Goldner, Whitney S.; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Moley, Jeffrey F.; Pillarisetty, Venu G.; Saltz, Leonard; Schteingart, David E.; Shah, Manisha H.; Shibata, Stephen; Strosberg, Jonathan R.; Vauthey, Jean-Nicolas; White, Rebekah; Yao, James C.; Freedman-Cass, Deborah A.; Dwyer, Mary A. (2012). "Neuroendocrine Tumors". Journal of the National Comprehensive Cancer Network. 10 (6): 724–764. doi:10.6004/jnccn.2012.0075. ISSN 1540-1405.
  2. Kunz, Pamela L.; Reidy-Lagunes, Diane; Anthony, Lowell B.; Bertino, Erin M.; Brendtro, Kari; Chan, Jennifer A.; Chen, Herbert; Jensen, Robert T.; Kim, Michelle Kang; Klimstra, David S.; Kulke, Matthew H.; Liu, Eric H.; Metz, David C.; Phan, Alexandria T.; Sippel, Rebecca S.; Strosberg, Jonathan R.; Yao, James C. (2013). "Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors". Pancreas. 42 (4): 557–577. doi:10.1097/MPA.0b013e31828e34a4. ISSN 0885-3177.
  3. Bourcier, Matthew E.; Vinik, Aaron I. (2013). "Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)". Pancreas. 42 (2): 348–352. doi:10.1097/MPA.0b013e31825c53fa. ISSN 0885-3177.



Template:WikiDoc Sources